Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study

American Journal of Nephrology

Volumn 43, Issue 6, 2016, Pages 431-440

  Cohen, Jordana B ^a   Stephens Shields, Alisa J ^b   Denburg, Michelle R ^b,c   Anderson, Amanda H ^b   Townsend, Raymond R ^a   Reese, Peter P ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Chronic kidney disease; Hypertension; Obesity; Renin angiotensin system blockade

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLACK PERSON; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED KINGDOM; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 84977652800     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000446862     Document Type: Article

References (67)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-1727.
2. Ogden CL, Carroll MD, Kit BK, Flegal KM: Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: 806-814.
3. Boniface S, Bridges S, Craig R, Darton R, Fuller E, Hancock R, Henderson C, Knott C, Mandalia D, Mindell J, Moody A, Morciano M, Ng Fat L, Oyebode O, Robinson C, Sadler K, Sutton R, Wittenberg R: Health Survey for England 2013: Adult Anthropometric Measures, Overweight and Obesity. Health and Social Care Information Centre, Leeds: Department of Epidemiology and Public Health, University College London, 2014.
4. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M: Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-825.
5. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezène F, Berthoux F: Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727.
6. Berthoux F, Mariat C, Maillard N: Overweight/ obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant 2013; 28(suppl 4):iv160-iv166.
7. Manson JE, Skerrett PJ, Greenland P, VanItallie TB: The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med 2004; 164: 249-258.
8. Iseki K, Ikemiya Y, Fukiyama K: Predictors of end-stage renal disease and body mass index in a screened cohort. Kidney Int Suppl 1997; 63:S169-S170.
9. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-1876.
10. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28.
11. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in U. S. Adults. Ann Intern Med 2004; 140: 167-174.
12. Lea J, Cheek D, Thornley-Brown D, Appel L, Agodoa L, Contreras G, Gassman J, Lash J, Miller ER 3rd, Randall O, Wang X, McClellan W; AASK Study Investigators: Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis 2008; 51: 732-740.
13. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD: Metabolic syndrome and kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373.
14. Townsend RR, Anderson AH, Chen J, Gadebegku CA, Feldman HI, Fink JC, Go AS, Joffe M, Nessel LA, Ojo A, Rader DJ, Reilly MP, Teal V, Teff K, Wright JT, Xie D: Metabolic syndrome, components, and cardiovascular disease prevalence in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Nephrol 2011; 33(6):477-484.
15. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
16. Praga M, Hernandez E, Morales E, Campos AP, Valero MA, Martinez MA, Leon M: Clinical features and long-term outcome of obesityassociated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 16: 1790-1798.
17. Amann K, Benz K: Structural renal changes in obesity and diabetes. Semin Nephrol 2013; 33: 23-33.
18. Saxena AB, Myers BD, Derby G, Blouch KL, Yan J, Ho B, Tan JC: Adaptive hyperfiltration in the aging kidney after contralateral nephrectomy. Am J Physiol Renal Physiol 2006; 291:F629-F634.
19. Zhuo JL, Li XC: New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 2011; 32: 1551-1565.
20. Cassis LA, Police SB, Yiannikouris F, Thatcher SE: Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 2008; 10: 93-98.
21. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217.
22. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278:F817-F822.
23. Hall JE, Brands MW, Dixon WN, Smith MJ Jr: Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 1993; 22: 292-299.
24. Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610-615.
25. Thethi T, Kamiyama M, Kobori H: The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012; 14: 160-169.
26. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y: The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486.
27. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
28. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebocontrolled trials. Am J Kidney Dis 2000; 35: 695-707.
29. Chiurchiu C, Remuzzi G, Ruggenenti P: Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: The data of the meta-analyses. J Am Soc Nephrol 2005; 16(suppl 1):S58-S63.
30. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.
31. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.
32. Maki DD, Ma JZ, Louis TA, Kasiske BL: Longterm effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073-1080.
33. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK: Body mass index and angiotensindependent control of the renal circulation in healthy humans. Hypertension 2005; 46: 1316-1320.
34. THIN Data Statistics 2014. http://csdmruk. cegedim. com/ (December 1, 2014).
35. Lewis JD, Bilker WB, Weinstein RB, Strom BL: The relationship between time since registration and measured incidence rates in the general practice research database. Pharmacoepidemiol Drug Saf 2005; 14: 443-451.
36. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; Ckd-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
37. Office for National Statistics: Census, Key Statistics and Quick Statistics for Local Authorities in the United Kingdom-Part 1 2011. http://www. ons. gov. uk/ons/index. html (cited November 1, 2013).
38. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
39. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
40. Townsend P: Poverty in the United Kingdom. London, Allen Lane and Penguin Books, 1979.
41. Chirinos JA, Franklin SS, Townsend RR, Raij L: Body mass index and hypertension hemodynamic subtypes in the adult US population. Arch Intern Med 2009; 169: 580-586.
42. De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G, Minutolo R: Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013; 61: 2461-2467.
43. De Nicola L, Borrelli S, Gabbai FB, Chiodini P, Zamboli P, Iodice C, Vitiello S, Conte G, Minutolo R: Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease. Kidney Blood Press Res 2011; 34: 58-67.
44. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I: Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-172.
45. Hirata A, Maeda N, Nakatsuji H, Hiuge-Shimizu A, Okada T, Funahashi T, Shimomura I: Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochem Biophys Res Commun 2012; 419: 182-187.
46. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino RB Sr, Wang TJ, Vasan RS: Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: The Framingham offspring study. Circulation 2007; 116: 984-992.
47. de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-47.
48. Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller ER 3rd, Rahman M, Steigerwalt S, Weir M, Wright JT Jr, Feldman HI; Chronic Renal Insufficiency Cohort Study Investigators: Time-updated systolic blood pressure and the progression of chronic kidney disease: A cohort study. Ann Intern Med 2015; 162: 258-265.
49. Kovesdy CP, Lu JL, Molnar MZ, Ma JZ, Canada RB, Streja E, Kalantar-Zadeh K, Bleyer AJ: Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014; 174: 1442-1449.
50. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic kidney disease: A KDIGO controversies conference report. Kidney Int 2011; 80: 17-28.
51. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
52. Andraws R, Brown DL: Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006-1012.
53. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
54. Joffe MM, Ten Have TR, Feldman HI, Kimmel SE: Model selection, confounder control, and marginal structural models: review and new applications. Am Stat 2004; 58: 272-279.
55. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.
56. Cole SR, Hernán MA: Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656-664.
57. Gilg J, Pruthi R, Fogarty D: UK renal registry 17th annual report: chapter 1 UK renal replacement therapy incidence in 2013: national and centre-specific analyses. Nephron 2015; 129(suppl 1):1-29.
58. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
59. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693.
60. Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, Manns BJ, Tonelli M, Hemmelgarn BR: Assessing the validity of surrogate outcomes for ESRD: A meta-analysis. J Am Soc Nephrol 2015; 26: 2289-2302.
61. Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C; REIN Study Group: ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol 2011; 22: 1122-1128.
62. Alicic R, Tuttle KR: Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy? Curr Hypertens Rep 2007; 9: 393-402.
63. Delanaye P, Mariat C: The applicability of eGFR equations to different populations. Nat Rev Nephrol 2013; 9: 513-522.
64. Delanaye P, Krzesinski JM: Indexing of renal function parameters by body surface area: intelligence or folly? Nephron Clin Pract 2011; 119:c289-c292.
65. Eriksen BO, Melsom T, Mathisen UD, Jenssen TG, Solbu MD, Toft I: GFR normalized to total body water allows comparisons across genders and body sizes. J Am Soc Nephrol 2011; 22: 1517-1525.
66. Bouquegneau A, Vidal-Petiot E, Vrtovsnik F, Cavalier E, Rorive M, Krzesinski JM, Delanaye P, Flamant M: Modification of diet in renal disease versus chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in obese patients. Nephrol Dial Transplant 2013; 28(suppl 4):iv122-iv130.
67. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl 2013; 3: 1-150.